SeaSpine released preliminary financial results for the company's first quarter as a separate entity from Integra LifeSciences.
Here are six things to know from the report:
1. The company's total revenue for the second quarter is expected to hit $33.5 million, down 6 percent for the same period last year.
2. Orthobiologics revenue is projected to increase 1 percent to $17 million.
3. The spinal fusion hardware revenue will be down 13 percent to $16.5 million for the second quarter.
4. Full-year revenue is expected to reach $133 million to $139 million, flat or down 4 percent compared with the same period last year. This is unchanged from the previous guidance Integra LifeSciences projected.
5. SeaSpine became an independent company July 1 and is investing in innovation and growth initiatives. The orthobiologics platform is the leading platform.
6. President and CEO Keith Valentine reported the company has a robust research and development pipeline that includes spinal fusion hardware products recently launched. The company expects to launch additional products in the second half of this year.